Effects on Quality of Life and Rehabilitation Therapy in Low Dose of Rotigotine in Post-Stroke Patients with Vascular Parkinsonism and Obstructive Sleep Apnoea Syndrome

Marchitto N^1*, Sindona F², Ceratti U², Fabrizio A³, Maietta A⁴, Monaco P⁵, Dalmaso S⁶ and Raimondi G⁷

¹Medical Director, Alfredo Fiorini Hospital, Terracina, Italy

²Specializing Doctor, Department of Internal Medicine, Sapienza University of Rome, Italy

³Nursing student of Sapienza University of Roma, Italy

⁴Medical Director, Santa Maria Goretti Hospital, Latina, Italy

⁵Vascular Surgeon, Director of Echo-doppler Ambulatory, Asl Latina, Italy

⁶Director of Ruolo, Alfredo Fiorini Hospital, Terracina, Italy

⁷Associated Professor of Internal Medicine, Department of Medico-surgical Sciences and Biotechnologies, Sapienza University of Roma, Italy

*Corresponding Author : Dr. Nicola Marchitto
Specialist in Geriatry and Gerontology, Medical Assistant, Department of Internal Medicine, Alfredo Fiorini Hospital, Terracina, Italy
Tel: +393277064979
Fax: +390773708752
E-mail: n.marchitto@ausl.latina.it

Received: May 23, 2017 Accepted: June 01, 2017 Published: June 08, 2017

Citation: Marchitto N, Sindona F, Ceratti U, Fabrizio A, Dalmaso S (2017) Effects on Quality of Life and Rehabilitation Therapy in Low Dose of Rotigotine in Post-Stroke Patients with Vascular Parkinsonism and Obstructive Sleep Apnoea Syndrome. J Sleep Disord: Treat Care 6:3. doi: 10.4172/2325-9639.1000196

Stroke is a frequent cause of disability in U.S.A. (200.000/ year). Aim: The aim of this study is to underline the effect of low dose of Rotigotine patches 2 mg/24 h, a complete dopamine agonist with continuous dopaminergic stimulation through the transdermal administration, in elderly with recent stroke and vascular Parkinsonism about quality of life and adherence to rehabilitation therapy. Methods: We have enrolled 6 elderly patients (3 males and 3 females, range age 60 – 95 years) with recent ischemic and vascular Parkinsonism. We have evaluated quality of life and cognitive function with UPDRS part III, MMSE, ADL, IADL and Morinsky Scale. At the same time we have evaluated the adherence to therapy and timing of rehabilitation therapy before and post-administration of Rotigotine 2 mg/24 hours. Conclusion: In conclusion, Rotigotine could be a new useful approach in the treatment of elderly patients with recent ischemic and hemorrhagic stroke correlated with vascular Parkinsonism which can lead to an akinesia with the need to start rehabilitation therapy. Our preliminary data gives comfortable results but, at this time, we have enrolled only few patients to give conclusive results.